FDA Denies Approval for Patisiran in ATTR Cardiomyopathy FDA Denies Approval for Patisiran in ATTR Cardiomyopathy

In a complete response letter, the FDA said the clinical meaningfulness of patisiran ' s effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Cardiology News Alert Source Type: news